Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia

4 Issues per year


IMPACT FACTOR 2016: 1.148

CiteScore 2016: 0.84

SCImago Journal Rank (SJR) 2016: 0.279
Source Normalized Impact per Paper (SNIP) 2016: 0.488

Open Access
Online
ISSN
1452-8266
See all formats and pricing
More options …
Volume 30, Issue 2

Issues

False Positive Values of Biomarkers of Prenatal Screening on Chromosomopathy as Indicators of a Risky Pregnancy

Jasmina Durković / Luka Anđelić / Bojana Mandić / Denis Lazar
Published Online: 2011-02-03 | DOI: https://doi.org/10.2478/v10011-011-0010-x

False Positive Values of Biomarkers of Prenatal Screening on Chromosomopathy as Indicators of a Risky Pregnancy

Genetic screening on chromosomopathy has been performed on 2000 pregnant women in their first trimester of pregnancy by determining Pregnancy associated plasma protein-A and free-beta HCG biomarkers in maternal serum. After obtaining a normal fetal karyotype, the pathological values of the biomarkers have been correlated with other pregnancy disorders, and the possible causes of the positive genetic screening have been tested. 340 false positive biomarkers (17%) have been detected. The increased free-beta HCG (48.24%) had a significant influence. A significant correlation (p > 0.01) between the increased free-beta HCG and bleeding during pregnancy has been established. Complications occurred in 78.52% pregnancies with pathological biomarkers, MISSed in 13.82%, miscarriages in 10.88%, induced pregnancy terminations caused by fetal anomalies in 8.82% and births with disturbed fetal vitality in 45%. The research results have shown a significant correlation (p > 0.01) between the increased value of the free-beta HCG biomarkers and fetal hypoxia. The false positive genetic screening, caused by the increased free-beta HCG, can indicate placental dysfunction and fetal vitality disruption.

Lažno Pozitivne Vrednosti Biomarkera Prenatalnog Skrininga na Hromozomopatije Kao Pokazatelji Rizične Trudnoće

Kod 2000 trudnica urađen je u prvom trimestru trudnoće genetski skrining na hromozomopatije određivanjem biomarkera Pregnancy associated plasma protein-A i free-beta-HCG u maternalnom serumu. Posle dobijanja normalnog kariotipa fetusa, patološke vrednosti biomarkera su korelisane sa drugim poremećajima trudnoće kako bi se ispitali mogući uzroci pozitivnog genetskog skrininga. Otkriveno je ukupno 340 lažno pozitivnih nalaza biomarkera (17%). Značajan udeo imao je povišeni free-beta-HCG (48,24%). Utvrđena je značajna povezanost (p>0,01) povišenog free-beta-HCG i krvarenja u trudnoći. U 78,52% trudnoća sa patološkim biomarkerima nastale su komplikacije: 13,82% MISSed, 10,88% spontani pobačaj, 8,82% indukovani prekid trudnoće zbog anomalija ploda i 45% porođaja sa poremećajem fetalnog vitaliteta. Rezultati istraživanja su pokazali veoma značajnu povezanost (p>0,01) između povećane vrednosti biomarkera free-beta-HCG i fetalne hipoksije. Lažno pozitivan genetski skrining uzrokovan povišenim free-beta-HCG može da bude pokazatelj placentarne disfunkcije i poremećaja fetalnog vitaliteta.

Keywords: prenatal screening; chromosomopathy; risky pregnancy; false positive values

Keywords: prenatalni skrining; hromozomopatije; rizična trudnoća; lažno pozitivne vrednosti

  • Brizot ML, Snijders RJM, Bersinger NA, Kuhn P, Nicolaides KH. Maternal serum pregnancy associated placental protein-A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy. Obstet Gynecol 1994; 84: 918-22.Google Scholar

  • Haddow JE, Palomaki GE, Knight GJ et al. Screening of maternal serum for fetal. Down's syndrome in the first trimester. N Engl J Med 1998; 338: 955-61.Google Scholar

  • Powell KJ, Grudzinskas JG. Screening for Down syndrome in the first trimester. Reprod Fertil Dev 1995; 7: 1413-17.Google Scholar

  • De Basio P, Siccardi M, Volpe G. First trimester screening for Down syndrome using nuchal translucency measurement with free-beta HCG and PAPP-A between 10 and 13 weeks of pregnancy - the combined test. Prenat Diagn 1999; 19: 360-3.Google Scholar

  • De Graf IM, Van Bezouw SM, Jacobs ME. First trimester noninvasive prenatal diagnosis of triploidy. Prenat Diagn 1999; 19: 175-7.CrossrefGoogle Scholar

  • Spencer K, Sauter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free-beta human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231-7.Web of ScienceGoogle Scholar

  • Krantz DA, Hallchan TW, Orlando F, Buchanan P, Larsen JW, Macri JN. First trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000; 96: 207-13.Google Scholar

  • Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening of chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-step clinic: a review of three years prospective experience. Br J Obstet Gynaecol 2003; 110 (3): 281-6.Google Scholar

  • Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, et al. First Trimester Screening for Trisomies 21 and 18. New Engl J Med 2003; 349: 1405-13.Google Scholar

  • Brigatti KW, Malone FD. First trimester screening for aneuploidy. Obstet Gynecol Clin North Am 2004; 31 (1): 1-20.CrossrefGoogle Scholar

  • Wald NJ, Bestwick J, Morris JK. Cross-trimester marker rations in prenatal screening for Down syndrome. Prenat Diagn 2006; 26: 514-23.Google Scholar

  • Wald NJ, Huttly WJ, Rudnicka AR. Prenatal screening for Down syndrome: the problem of recurrent false-positives. Prenat Diagn 2004; 24 (5): 389-92.PubMedCrossrefGoogle Scholar

  • Summers AM, Huang T, Meier C, Wyatt PR. The Implications of a False Positive Second Trimester Serum Screen for Down Syndrome. Obstet Gynecol 2003; 101: 1301-6.Google Scholar

  • Evers-Kiebooms G, Nys K, Decruyenaere M, Witters I, Fryns JP. Triple Test Screening for Down Syndrome: Looking Back on False-Positive Results and Having or Not Having a Triple test in Subsequent Pregnancies. Community Genetich 2001; 4: 43-9.Google Scholar

  • Bujišić N. Effects of serum-alot confact time on second-trimester prenatal screening markers and their stability on serum. Journal of Medical Biochemistry 2010; 29: 84-88.Web of ScienceGoogle Scholar

  • PRISCA PRENATAL RISK CALCULATION. The screening program under Microsoft Windows. Typolog software. http://www.typolog.de

  • Wald NJ, Morris JK, Ibison J, Wu T, George LM. Screening in early pregnancy for pre-eclampsia using markers from the Down's syndrome Quadruple test. Wolfson Institute of Preventive Medicine. Preliminary results of selected work in progress on Antenatal Screening 2007. MEDLINE.Google Scholar

  • Muller F, Savety L, Le Fiblec B, Bussires L, Ndayizamba G, Claude Colan J, Giraudet P. Maternal serum human chorionic gonadotropin level at fifteen weeks is a predictor for preeclampsia. AMJ Obstet Gynecol 1996; 175: 37-40.Google Scholar

  • Pergament E, Estain AK, Fiddber M, Cho NK, Kupferninc MJ. Adverse pregnancy outcome after a false-positive screening for Down's syndrome using multiple markers. Obstet Gynecol 1995; 13: 58-62.Google Scholar

  • Gonen R, Perz R, David M, Dar H, Merk Samer R, Sharf M. The association between unexplained second trimester maternal serum HCG elevation and pregnancy complications. Obstet Gynecol 1992; 80: 83-6.Google Scholar

  • Van Rijin M, Van der Schouw YT, Hasenaars AM, Visser GH, Christieans GC. Adverse obstetric outcome in low-and high-risk pregnancies: predictive value of maternal serum screening. Obstet Gynecol 1999; 94 (6): 929-34.CrossrefGoogle Scholar

  • Chandra S, Scott H, Dodds L, Watts C, Blight C, Van Der Hof M. Unexplained elevated maternal serum alphafetoprotein and/or human chorionic gonadotropin and risk of adverse outcomes. Am J Obstet Gynecol 2003; 189 (3): 775-81.Google Scholar

About the article


Published Online: 2011-02-03

Published in Print: 2011-01-01


Citation Information: Journal of Medical Biochemistry, Volume 30, Issue 2, Pages 126–130, ISSN (Online) 1452-8266, ISSN (Print) 1452-8258, DOI: https://doi.org/10.2478/v10011-011-0010-x.

Export Citation

This content is open access.

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Comments (0)

Please log in or register to comment.
Log in